Skip to main content

COVID Disease — Monoclonal Antibodies — Clinical Pathway: All Settings

Active COVID-19, Clinical Pathway — All Settings

Treatment of COVID-19 with Anti-SARS-CoV-2 Monoclonal Antibodies

Update 12/10/2022

Effective 12/10/2022, there are no monoclonal antibodies available for treatment of COVID-19 active against currently circulating SARS-CoV-2 variants. Bamlanivimab-etesevimab, casirivimab-imdevimab, sotrovimab, and bebtelovimab have all been deauthorized by the FDA given that they are not active.

 

Jump back to top